DE69413955D1 - Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel - Google Patents

Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel

Info

Publication number
DE69413955D1
DE69413955D1 DE69413955T DE69413955T DE69413955D1 DE 69413955 D1 DE69413955 D1 DE 69413955D1 DE 69413955 T DE69413955 T DE 69413955T DE 69413955 T DE69413955 T DE 69413955T DE 69413955 D1 DE69413955 D1 DE 69413955D1
Authority
DE
Germany
Prior art keywords
derivative
mercaptoester
amid
ester
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69413955T
Other languages
English (en)
Other versions
DE69413955T2 (de
Inventor
Daniel Duan
James Stefely
David Schultz
Chester Leach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Publication of DE69413955D1 publication Critical patent/DE69413955D1/de
Application granted granted Critical
Publication of DE69413955T2 publication Critical patent/DE69413955T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
DE69413955T 1993-03-17 1994-03-16 Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel Expired - Fee Related DE69413955T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3214693A 1993-03-17 1993-03-17
PCT/US1994/002841 WO1994021229A1 (en) 1993-03-17 1994-03-16 Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid

Publications (2)

Publication Number Publication Date
DE69413955D1 true DE69413955D1 (de) 1998-11-19
DE69413955T2 DE69413955T2 (de) 1999-04-01

Family

ID=21863354

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69413955T Expired - Fee Related DE69413955T2 (de) 1993-03-17 1994-03-16 Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel

Country Status (10)

Country Link
US (2) US5569450A (de)
EP (1) EP0689424B1 (de)
JP (1) JP3987963B2 (de)
KR (1) KR100321649B1 (de)
AU (1) AU679511B2 (de)
CA (1) CA2156408C (de)
DE (1) DE69413955T2 (de)
ES (1) ES2122261T3 (de)
NZ (1) NZ263686A (de)
WO (1) WO1994021229A1 (de)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
GB9620187D0 (en) * 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
AU2003204078B2 (en) * 1997-02-07 2006-08-17 Minnesota Mining And Manufacturing Company Biocompatible compounds for pharmaceutical drug delivery systems
AU761559B2 (en) * 1997-02-07 2003-06-05 Minnesota Mining And Manufacturing Company Biocompatible compounds for pharmaceutical drug delivery systems
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
AU4894697A (en) * 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
EP2258183A1 (de) * 1998-12-22 2010-12-08 The University of North Carolina at Chapel Hill Verbindungen und Verwendungen zur Behandlung von Atemwegeserkrankungen sowie zur Verabreichung von Arzneistoffen für die Atemwege
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
CN1440298A (zh) * 2000-01-25 2003-09-03 气体药品技术公司 药用气雾剂
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
AU2001276497B2 (en) 2000-08-05 2005-04-07 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
KR100831534B1 (ko) 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
SI1273292T1 (en) 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
AU2002337803A1 (en) * 2001-10-03 2003-04-14 Glaxo Group Limited Sustained release pharmaceutical compositions
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
ATE424186T1 (de) * 2001-12-21 2009-03-15 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
DE60228615D1 (de) * 2001-12-21 2008-10-09 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einer eine amid- und/oder estergruppe enthaltenden exzipientenverbindung
AU2002361850A1 (en) * 2001-12-21 2003-07-30 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CA2507522C (en) * 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
JP2007502288A (ja) 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ含有化合物
EP1658076B1 (de) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy- und arylalkylenoxy-substituierte imidazochinoline
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
BRPI0414856A (pt) 2003-10-03 2006-11-21 3M Innovative Properties Co imidazoquinolinas alcóxi-substituìdas
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005048945A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
KR101168620B1 (ko) * 2003-12-16 2012-08-03 넥타르 테라퓨틱스 Ｐｅｇ화된 소분자
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699847B1 (de) * 2003-12-30 2011-04-13 3M Innovative Properties Company Herstellungsverfahren von medizinischen zusammensetzungen
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
LT2767292T (lt) 2004-09-17 2016-12-12 Durect Corporation Palaikomosios vietinės anestezijos mišinys su saib
AU2005290068A1 (en) * 2004-09-24 2006-04-06 3M Innovative Properties Company Medicinal aerosol formulations and methods of synthesizing ingredients therefor
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006074003A2 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
KR20070116821A (ko) * 2005-03-14 2007-12-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 의약 제제용 생체적합성 중합체 화합물
EP1869043A2 (de) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridin-1,4-diamine und analoge davon
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
WO2007011763A2 (en) * 2005-07-15 2007-01-25 3M Innovative Properties Company Adhesive sheet and methods of use thereof
WO2007011764A2 (en) * 2005-07-15 2007-01-25 Bayer Schering Pharma Aktiengesellschaft Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20090123391A1 (en) * 2006-03-22 2009-05-14 3M Innovative Properties Company Novel Formulations
AR060039A1 (es) * 2006-03-22 2008-05-21 3M Innovative Properties Co Formulaciones novedosas
CA2649895C (en) * 2006-04-19 2013-03-26 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
NO343857B1 (no) * 2006-07-18 2019-06-24 Meda Ab Immunresponsmodifiserende skumformuleringer
GB0614621D0 (en) 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
US8003663B2 (en) 2006-08-01 2011-08-23 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
GB0620700D0 (en) 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
WO2008079295A1 (en) * 2006-12-22 2008-07-03 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
BRPI0811430A2 (pt) * 2007-05-10 2015-06-23 Novadel Pharma Inc Composições anti-insônia e processos
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
CA2706658A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
LT2320905T (lt) 2008-08-11 2017-09-11 Glaxosmithkline Llc Naujieji adenino dariniai
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP2408916A2 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von ctgf (connective tissue growth factor) unter verwendung von sina (short interfering nucleic acid)
EA201171144A1 (ru) 2009-03-19 2012-04-30 Мерк Шарп Энд Домэ Корп. ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004282A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp, RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
UY32571A (es) 2009-04-24 2010-11-30 Glaxo Group Ltd Compuestos derivados de pirazol amida
WO2010147947A2 (en) 2009-06-16 2010-12-23 Schering Corporation NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
PT2534149E (pt) 2010-02-10 2014-12-23 Glaxosmithkline Llc Maleato de 6-amino-2-{[(1s)-1-metilbutil]oxi}-9-[5-(1- piperidinil)pentil]-7,9-di-hidro-8h-purin-8-ona
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US9233997B2 (en) 2010-08-26 2016-01-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
ES2532213T3 (es) 2010-10-21 2015-03-25 Glaxo Group Limited Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP3327125B1 (de) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
CA2838030A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
GB201210580D0 (en) 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
WO2013192620A1 (en) 2012-06-22 2013-12-27 Quantrx Biomedical Corporation Method for obtaining fetal cells and fetal cellular components
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve
WO2014088920A1 (en) 2012-12-06 2014-06-12 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
RU2676684C2 (ru) 2014-02-20 2019-01-10 ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
EP3218377B1 (de) 2014-11-13 2022-04-13 GlaxoSmithKline Biologicals SA Zur behandlung von allergischen erkrankungen und anderen entzündlichen zuständen geeignete adenin derivate
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
KR20180080328A (ko) 2015-11-18 2018-07-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 리바비린의 약학적 조성물
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
EP3390384B1 (de) 2015-12-17 2021-09-15 Astex Therapeutics Limited Chinolin-3-5-carboxamide als h-pgds-inhibitoren
CN113286586A (zh) 2018-06-22 2021-08-20 Ucl商业有限公司 新化合物
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2733252A (en) * 1956-01-31 Salts of fatty acid esters of lactylic
US2362511A (en) * 1939-11-21 1944-11-14 Du Pont Modified glycolide resins
US2789992A (en) * 1951-12-12 1957-04-23 Patterson Co C Acyl lactylic acid products
US3098795A (en) * 1958-11-04 1963-07-23 Dyk & Company Inc Van Cosmetic compositions containing lactic acid esters of fatty alcohols
US3728447A (en) * 1970-03-03 1973-04-17 Patterson Co C Fatty acid lactylates and glycolates for conditioning hair
US3933825A (en) * 1973-05-14 1976-01-20 Bristol-Myers Company Amine salts of acyl lactylic acids
JPS5825720B2 (ja) * 1974-12-05 1983-05-28 ライオン株式会社 フンリユウジヨウセンジヨウザイソセイブツ
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
EP0164817B1 (de) * 1984-03-21 1991-01-23 Imperial Chemical Industries Plc Detergens
LU85863A1 (fr) * 1985-04-22 1986-11-05 Oreal Composition cosmetique pour le traitement des cheveux,notamment des cheveux gras,a base d'un extrait de millefeuille(achilea millefolium l)
JPH0625090B2 (ja) * 1987-02-12 1994-04-06 花王株式会社 毛髪化粧料
US5008028A (en) * 1988-12-14 1991-04-16 The Lubrizol Corporation Liquid compositions containing carboxylic esters
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
EP0636362B1 (de) * 1990-03-23 1999-12-22 Minnesota Mining And Manufacturing Company Anwendung von löslichen fluorhaltigen Tensiden zur Herstellung von Aerosol-Präparaten mit dosierter Abgabe
EP0536204B1 (de) * 1990-06-27 1994-04-06 Minnesota Mining And Manufacturing Company Anwendung von löslichen fluorhaltigen tensiden zur herstellung von aerosol-präparaten mit dosierter abgabe
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
CA2085884C (en) * 1990-06-29 2001-12-04 Asit Somani Pressurized hydrofluorocarbon aerosol compositions
JPH04169554A (ja) * 1990-11-01 1992-06-17 Sanken Kako Kk ネオ酸エステルの製造方法
US5250293A (en) * 1991-04-22 1993-10-05 Gleich Gerald J Method for the treatment of hypersensitivity diseases by administration of anionic polymers
TW247878B (de) * 1991-07-02 1995-05-21 Takeda Pharm Industry Co Ltd
IL103238A (en) * 1991-09-25 1995-07-31 Fisons Plc Pressed aerosol preparations

Also Published As

Publication number Publication date
NZ263686A (en) 1997-09-22
JPH08507793A (ja) 1996-08-20
CA2156408C (en) 2005-02-15
WO1994021229A1 (en) 1994-09-29
AU6446894A (en) 1994-10-11
EP0689424A1 (de) 1996-01-03
KR100321649B1 (ko) 2002-07-22
EP0689424B1 (de) 1998-10-14
US5725841A (en) 1998-03-10
ES2122261T3 (es) 1998-12-16
CA2156408A1 (en) 1994-09-24
US5569450A (en) 1996-10-29
KR960700688A (ko) 1996-02-24
JP3987963B2 (ja) 2007-10-10
DE69413955T2 (de) 1999-04-01
AU679511B2 (en) 1997-07-03

Similar Documents

Publication Publication Date Title
DE69413955T2 (de) Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel
DE69231857T2 (de) Aerosolzusammensetzungen
GB9516072D0 (en) Improved compositions containing organic compounds
DE69405719D1 (de) Aerosolzubereitung, enthaltend ein aus einem diol-disäure-derivat abgeleitetes dispergiermittel
FI935194A (fi) Foerfarande foer dubbelriktad oeverfoering i ett cellulaert mobilradiokommunikationssystem, i vilket foerfarande olika basstationer anvaends foer downlink- och uplink-foerbindelse
GB9516081D0 (en) Improved compositions containing organic compounds
BR9301551A (pt) Composicao de aerosol antiperspirante
FI946037A (fi) Parannettuja maanviljelykoostumuksia
GB9315914D0 (en) Novel compound
PL327978A1 (en) Substituted sulphonylamino(thio)carbonyl compounds as herbicidal substances
GB9420114D0 (en) Substituted cyclic derivatives as novel antidegenerative agents
GB9523222D0 (en) Improved compositions containing organic compounds
BR9406627A (pt) Composições antiparasiticas
KR950700285A (ko) 약제로서 유용한 질소 함유 헤테로시클릭 화합물(Nitrogen containing heterocyclk compounds useful as pharmaceuticals)
GB2307915B (en) Improved compositions containing organic compounds
GB9612645D0 (en) Improved compositions containing organic compounds
NZ248227A (en) 2-phenylacrylic acid ester derivatives, fungicidal compositions thereof
EP0708765A4 (de) Substituierte piperazinylkampher-derivate als oxytoxin-antagonisten
GB9402324D0 (en) Novel piperidine-triazine compounds suitable for use as stabilizers for organic materials
GB9406236D0 (en) Novel piperidine-triazine compounds suitable for use as stabilizers for organic materials
BR9304405A (pt) Composição contendo carbonila
GB9302567D0 (en) Novel compound
EP0545861A3 (en) Diphenylacetic acid derivatives as stabilisers for organic material
DE496418T1 (de) Klebemittelstoffzusammensetzung aus alphacyanakrylsaeureester.
BR9304462A (pt) Composição contendo carbonil, e, composição de material

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee